Fact-checked by Grok 2 weeks ago

Mumps

Mumps is an acute, self-limited viral illness caused by the mumps virus, a single-stranded RNA paramyxovirus belonging to the genus Rubulavirus in the family Paramyxoviridae, that primarily affects the salivary glands, most commonly resulting in painful swelling of one or both parotid glands known as parotitis.^[1]^[2] The infection typically begins with a prodrome of low-grade fever, headache, myalgia, fatigue, and anorexia lasting 1–2 days, followed by the characteristic glandular swelling that persists for 3–7 days, though up to 30–40% of cases may be subclinical without noticeable parotitis.^[2]^[3] Transmission occurs primarily through direct contact with respiratory droplets, saliva, or mucus from an infected person, with the virus shed from 7 days before to 9 days after parotitis onset, rendering it highly contagious in close-contact settings like schools or households, where secondary attack rates can exceed 80% among susceptible individuals.^[4]^[2] Prior to widespread vaccination, mumps was endemic worldwide with annual incidence peaks in winter-spring among school-aged children, but empirical surveillance data show dramatic reductions post-vaccine introduction, though not elimination.^[3] Notable complications arise in 10–20% of cases, including orchitis in 20–30% of post-pubertal males (potentially leading to testicular atrophy or infertility in rare instances), aseptic meningitis in up to 10%, and rarer events like encephalitis, oophoritis, or pancreatitis, with severity linked to host age and immune status rather than viral strain variations.^[2]^[3] The live attenuated measles-mumps-rubella (MMR) vaccine, administered in two doses, confers 78–88% effectiveness against clinical disease after two doses, yet longitudinal serological studies demonstrate waning humoral immunity over 15–25 years, contributing to outbreaks in highly vaccinated cohorts such as universities, where two-dose coverage exceeds 90% but secondary vaccine failure predominates.^[5]^[6] This underscores the causal role of time-dependent immune decay in resurgence dynamics, prompting investigations into third-dose boosting efficacy.^[5]

Etymology and Historical Context

Etymology

The term "mumps" entered English around 1600 as a plural form of "mump," an archaic verb meaning to grimace, whine, or mutter with pursed lips, reflecting the facial distortion and painful swelling characteristic of parotid gland inflammation in affected individuals.^[7] This usage likely drew from earlier Middle English associations with mumbling or sulking expressions caused by oral discomfort, predating formal medical descriptions but capturing the disease's visible lumps or "mumps" on the face.^[8] Medically, the condition was long termed parotitis, derived from Ancient Greek parōtîtis, combining parōtís ("gland beside or behind the ear," from para- "beside" + ōús "ear") with -îtis denoting inflammation, emphasizing the primary site of salivary gland involvement.^[9] This nomenclature, attested in English by the late 18th century, underscored descriptive anatomy over etiology and was used interchangeably with "mumps" in clinical texts to denote epidemic outbreaks of glandular swelling.^[10] Following experimental transmission studies in the 1930s confirming a filterable viral agent and successful isolation of the virus in embryonated eggs in 1945, nomenclature shifted toward virological precision, with the pathogen classified as Mumps orthorubulavirus under the family Paramyxoviridae, distinguishing it from bacterial parotitis and standardizing "mumps" as the eponymous viral disease.^[11]^[12]

Early recognition and epidemics

The earliest detailed clinical description of mumps dates to the 5th century BC in the Hippocratic Corpus, particularly the first book of Epidemics, which recounts an outbreak of parotitis—swelling of the parotid salivary glands—on the Greek island of Thasos around 410 BC. Hippocrates characterized the illness by unilateral or bilateral glandular enlargement, often with fever, pain upon swallowing, and complications such as orchitis or cerebral involvement, while noting its tendency to spread within households and communities, establishing early recognition of its contagious pattern.^[11]^[13] By the 19th and early 20th centuries, mumps was well-documented as a cyclical childhood disease prone to epidemics in Europe and the United States, especially in settings with high densities of susceptible individuals such as schools and urban centers. In the U.S., surveillance from 1923 to 1932 recorded 239,230 cases across 70 cities, with larger populations experiencing near-annual outbreaks and smaller ones showing sporadic peaks, reflecting the virus's baseline transmission dynamics in unvaccinated societies where infection rates could reach substantial fractions of exposed groups.^[14] Military contexts amplified outbreak severity due to close confinement; during World War I, mumps emerged as a principal non-combat cause of lost duty days among U.S. forces in France, with an average annual hospitalization incidence of 55.8 per 1,000 personnel, underscoring the disease's disruptive potential in aggregated adult populations lacking prior immunity.^[15] The viral cause was definitively established in 1934 when researchers Claud D. Johnson and Ernest W. Goodpasture demonstrated transmission from saliva of acute human cases to rhesus monkeys, isolating a filterable, cytotropic agent that reproduced parotitis and orchitis, thereby confirming mumps as a distinct contagious viral entity rather than a mere complication of other infections.^[16]^[17]

Vaccine development and initial impact

The Jeryl Lynn strain of mumps virus was isolated in 1963 by virologist Maurice Hilleman from a throat swab taken from his five-year-old daughter, who had developed the disease.^[18] ^[19] Hilleman attenuated the virus through serial passage in cell culture to create a live vaccine candidate, which underwent clinical testing and was licensed in the United States in December 1967 as the monovalent Mumpsvax.^[20] ^[21] This formulation targeted children over one year of age, with initial recommendations from the Advisory Committee on Immunization Practices focusing on routine use for susceptible individuals in high-risk groups.^[20] In 1971, the mumps component was incorporated into the combined measles-mumps-rubella (MMR) vaccine, facilitating broader administration.^[22] Prior to vaccine licensure, mumps caused an estimated 152,000 to 186,000 reported cases annually in the United States during the mid-1960s, reflecting underreporting of a disease that infected most children before adolescence.^[23] Widespread vaccination programs led to a sharp decline, with reported cases falling to approximately 8,000 by 1977 and fewer than 3,000 by 1985, representing over a 97% reduction from pre-vaccine levels.^[24] ^[23] This empirical drop correlated directly with increasing vaccine coverage, which reached about 40% of U.S. children by 1974 through school-based mandates and routine pediatric immunization.^[22] Early clinical trials of the single-dose Jeryl Lynn vaccine demonstrated efficacy of approximately 95% against clinical mumps disease, based on protection against parotitis in controlled challenge studies and post-licensure surveillance.^[25] ^[26] However, serological and epidemiological data from the 1970s indicated incomplete prevention of subclinical or asymptomatic infections, as evidenced by detectable virus shedding or seroconversion in some vaccinated individuals exposed during outbreaks.^[26] These findings underscored the vaccine's primary role in averting symptomatic illness while highlighting limitations in achieving sterilizing immunity against viral transmission.^[25]

Resurgences in the vaccine era

Following the introduction of the live attenuated mumps vaccine in the United States in 1967 and its routine use in combination with measles and rubella vaccines from 1971, mumps incidence declined dramatically, from over 150,000 reported cases annually in the prevaccine era to fewer than 5,000 by the early 2000s, with similar reductions observed globally in countries implementing widespread vaccination programs.^[27] ^[28] However, this trend reversed starting in 2006, with reported U.S. cases rising to over 6,000 that year, primarily in multistate outbreaks among college students in settings with two-dose vaccination coverage exceeding 90%.^[29] ^[30] These clusters highlighted transmission despite high immunization levels, occurring in close-contact environments like dormitories rather than due to broad vaccine hesitancy.^[31] The resurgence intensified from 2016 to 2019, with annual U.S. cases peaking between 2,251 and 6,369, predominantly affecting vaccinated young adults aged 18-24 in universities, schools, and workplaces.^[32] ^[33] In 2019 alone, 3,474 cases were reported, many linked to waning vaccine-induced immunity rather than incomplete coverage, as evidenced by outbreaks in populations with documented two-dose receipt.^[23] Mathematical modeling of transmission dynamics attributes this pattern primarily to the gradual decline in protective antibody levels over time post-vaccination, particularly after the second dose, enabling sustained circulation in highly vaccinated groups.^[28] ^[34] Genomic surveillance of outbreak strains, predominantly genotype G wild-type viruses distinct from the genotype A Jeryl Lynn vaccine strain, confirms ongoing community transmission of non-vaccine-derived variants rather than widespread vaccine escape mutants.^[35] ^[36] While some antigenic variations between circulating strains and vaccine components have been noted, potentially contributing to reduced neutralization in previously immunized individuals, epidemiological data prioritize waning immunity as the dominant factor over primary vaccine failure or refusal.^[37] Outbreaks persisted into 2023-2025, with clusters in U.S. schools and universities prompting public health recommendations for third-dose MMR pilots in high-risk settings to bolster short-term protection amid close-contact exposures.^[32] ^[38]

Clinical Presentation

Incubation period and prodromal symptoms

The incubation period of mumps, defined as the time from viral exposure to the onset of symptoms, typically lasts 16 to 18 days, with a documented range of 12 to 25 days based on clinical observations and outbreak data.^[1]^[3] This variability reflects individual differences in viral replication and host immune responses, as evidenced by prospective studies tracking exposure in household and community settings.^[2] Prodromal symptoms emerge toward the end of the incubation period and are nonspecific, often including low-grade fever, malaise, headache, myalgia, and anorexia, which may persist for 1 to 2 days prior to the development of parotitis.^[39]^[2] These early signs arise from initial systemic viral dissemination, with empirical evidence from outbreak investigations confirming their fleeting and variable nature, sometimes extending to 3 to 5 days in adults compared to children.^[40] Approximately 20% to 40% of mumps infections remain subclinical, manifesting without noticeable symptoms but detectable through serological evidence of infection, such as IgM antibody detection or seroconversion.^[21]^[35] This proportion, derived from pre-vaccine era cohort studies and serological surveys, underscores the virus's capacity for asymptomatic transmission, contributing to underreporting in surveillance data.^[3]^[41]

Primary signs and symptoms

The hallmark sign of mumps is parotitis, involving painful, tender swelling of one or both parotid salivary glands in the cheek and jaw area, occurring in over 70% of symptomatic infections.^[2] Swelling typically peaks 1 to 3 days after prodromal symptoms and lasts approximately 5 days, with full resolution in about 10 days; unilateral involvement affects about 25% of cases, while other salivary glands such as submandibular or sublingual may swell in around 10%.^[39] Commonly associated symptoms include low-grade fever persisting 3 to 4 days, anorexia, malaise, headache, myalgia, and earache due to pressure from glandular enlargement, which elevates the earlobe and obscures the jawline angle.^[39]^[3] Orchitis, presenting as acute testicular pain and swelling, develops in up to 30% of post-pubertal males with mumps, while oophoritis occurs in fewer than 5% of post-pubertal females; these are infrequent primary features but notable in the clinical picture of older patients.^[3]^[2] In uncomplicated cases, the overall symptomatic phase resolves within 7 to 10 days.^[2]

Complications

Orchitis, inflammation of the testes, develops in 15–40% of postpubertal males infected with mumps virus, typically appearing 4–8 days after parotitis onset and affecting one testis in most cases, though bilateral involvement occurs in 10–30% of orchitis instances.^[2] Affected individuals experience painful testicular swelling, fever, and nausea, with symptoms resolving in 1–2 weeks in uncomplicated cases. Testicular atrophy follows in approximately 30% of involved testes, potentially leading to subfertility through impaired spermatogenesis, but sterility is rare, affecting less than 1% of overall mumps cases and confined primarily to severe bilateral atrophy.^[42] ^[43] Oophoritis, the ovarian counterpart, occurs in up to 5% of postpubertal females but seldom causes chronic fertility impairment.^[44] Pancreatitis arises in 4–7% of mumps patients, manifesting as abdominal pain, nausea, and elevated serum amylase levels, usually within one week of parotitis; it is generally self-limited without long-term sequelae.^[44] ^[2] Central nervous system complications are infrequent but include aseptic meningitis in 1–10% of cases, characterized by headache, stiff neck, and cerebrospinal fluid pleocytosis without bacterial growth, typically resolving without residual effects.^[44] ^[2] Encephalitis occurs in fewer than 0.1% of infections (0.02–0.3% per some estimates), potentially causing altered mental status, seizures, or hydrocephalus, with case-fatality rates up to 1–2% among affected individuals.^[40] Sensorineural deafness, a rare auditory nerve complication, affects about 0.005% (1 in 20,000) of patients, often unilaterally and permanently.^[2] Other uncommon sequelae, such as thyroiditis, may occur but rarely progress to chronic hypothyroidism based on available clinical data.^[45]

Etiology

Causative agent

The causative agent of mumps is the mumps virus (MuV), an enveloped virus with a non-segmented, negative-sense, single-stranded RNA genome belonging to the family Paramyxoviridae and genus Rubulavirus.^[11]^[46] The genome measures 15,384 nucleotides and encodes seven proteins: nucleoprotein (NP), phosphoprotein (P), matrix (M), fusion (F), small hydrophobic (SH), hemagglutinin-neuraminidase (HN), and large polymerase (L).^[46]^[47] The envelope incorporates the HN glycoprotein for host cell attachment via sialic acid receptors and neuraminidase activity, alongside the F glycoprotein enabling viral-host membrane fusion.^[11] These surface glycoproteins are key to viral entry and are targets for neutralizing antibodies.^[11] MuV comprises 12 genotypes (A–J and L), differentiated by polymorphisms in the SH gene, with genotype G predominating in the United States since 2006 and linked to vaccine-era resurgences.^[2]^[48] The virus exhibits relative genetic stability, with limited antigenic variation facilitating long-term vaccine efficacy against diverse strains, though genotype shifts occur over time.^[2] The viral etiology was established in 1934 through experiments by Johnson and Goodpasture, who transmitted mumps from infected patients to rhesus monkeys via filtered saliva, confirming a filterable agent as the cause.^[49] They further validated parotitis causation by inoculating the virus into the parotid ducts of parotidectomized human subjects, reproducing glandular inflammation.^[49] The virus was first isolated in embryonated eggs in 1945.^[11]

Viral structure and classification

The mumps virus (MuV) is an enveloped, pleomorphic virion measuring 100–300 nm in diameter, featuring a helical nucleocapsid core approximately 18 nm wide that encapsidates the genomic RNA. Electron microscopy reveals surface projections consisting of hemagglutinin-neuraminidase (HN) and fusion (F) glycoproteins, which facilitate attachment and entry, distinguishing MuV morphology from non-enveloped or differently spiked related pathogens. Cryo-electron microscopy studies have resolved nucleocapsid structures, including stacked-ring filaments and variable helical assemblies, underscoring the virus's structural plasticity.^[50]^[51]^[52] MuV possesses a non-segmented, linear, negative-sense, single-stranded RNA genome of about 15,300 nucleotides, organized into seven consecutive genes that encode nine proteins: nucleoprotein (N), phosphoprotein (P; with V and I variants produced via RNA editing), matrix (M), fusion (F), small hydrophobic (SH), hemagglutinin-neuraminidase (HN), and large polymerase (L). The N protein binds the genome to form the ribonucleoprotein complex, while P interacts with N and L to enable replication and transcription, core mechanisms shared among mononegaviruses but with MuV-specific protein sequences.^[53]^[54]^[55] Taxonomically, MuV is classified in the family Paramyxoviridae (order Mononegavirales), genus Orthorubulavirus, as its type species, differentiated from parainfluenza viruses (e.g., in genera Respirovirus or Orthorubulavirus) by gene order (including the SH gene between F and HN), antigenic specificity of HN, and serological assays detecting MuV-exclusive antibodies despite minor cross-reactivity. While paramyxoviruses exhibit overall antigenic stability, MuV shows genetic drift primarily in the HN gene, correlating with genotype diversity (e.g., 24 recognized genotypes via SH sequencing) but not major antigenic shifts.^[56]^[57]^[58]

Pathogenesis and Transmission

Pathogenic mechanisms

The mumps virus (MuV), a member of the genus Rubulavirus in the family Paramyxoviridae, initiates infection through inhalation of respiratory droplets containing the virus, which first targets epithelial cells in the upper respiratory tract or alveolar macrophages for primary replication.^[11] ^[59] Local replication in these sites leads to spread to regional lymph nodes, followed by viremia approximately 5-7 days post-infection, enabling systemic dissemination to target organs such as salivary glands, pancreas, testes, ovaries, and central nervous system tissues.^[21] ^[3] In salivary glands, particularly the parotid, MuV exhibits tropism facilitated by its hemagglutinin-neuraminidase (HN) protein binding to sialic acid receptors on glandular epithelial cells, with subsequent fusion mediated by the fusion (F) protein, allowing viral entry and intracellular replication.^[46] Viral propagation within acinar and ductal cells induces direct cytopathic effects, including cell necrosis, edema, hemorrhage, and perivascular infiltration of mononuclear cells, which contribute to glandular swelling observed in parotitis.^[11] Experimental studies and autopsy findings reveal that T-cell infiltration, driven by infected migrating lymphocytes, amplifies tissue damage through immune-mediated inflammation, though direct viral replication remains the primary driver of acinar destruction.^[60] For complications, viremic spread allows MuV to infect neural tissues via the choroid plexus or meningeal cells, leading to aseptic meningitis or encephalitis through endothelial disruption and perivascular cuffing; similarly, hematogenous dissemination to gonadal tissues causes orchitis or oophoritis via endothelial infection and leukocyte-mediated vascular damage.^[3] ^[11] In vitro and animal models confirm MuV's neurotropism and glandular affinity, with autopsy data showing viral antigens in affected CNS and gonadal parenchyma, underscoring hematogenous routes over neural retrograde spread.^[46] Subclinical infections may involve low-level viral persistence in lymphoid or epithelial reservoirs post-viremia, potentially enabling prolonged shedding without overt symptoms, though primary transmission relies on acute respiratory replication rather than chronic carriage.^[60] Knowledge gaps persist regarding exact persistence mechanisms, as human biopsy data are limited, but experimental evidence suggests infected T cells facilitate cryptic dissemination.^[60]

Routes of transmission and contagiousness

Mumps virus spreads primarily via direct contact with respiratory droplets expelled from the mouth, nose, or throat of an infected person during coughing, sneezing, or talking, as well as through saliva via activities like kissing or sharing drinking utensils or food.^[1] Transmission requires close proximity, with risk increasing alongside duration and intensity of contact, as the virus initially replicates in the upper respiratory tract.^[1] Fomite transmission via contaminated objects such as toys or surfaces touched by infected saliva is possible but plays a minimal role relative to droplet and direct contact routes.^[2] No arthropod or other biological vectors are involved in spreading the virus.^[1] Virus shedding in saliva begins as early as 7 days before parotitis onset and can persist up to 9 days afterward, rendering infected individuals contagious during this window; however, public health isolation guidelines typically specify the period from 2 days before to 5 days after parotitis onset to balance containment with practicality, given that peak transmissibility aligns with clinical symptoms.^[1] Asymptomatic shedding may occur but contributes less to overall transmission dynamics.^[61] The basic reproduction number (R₀) of mumps, representing the average secondary cases generated by one infected individual in a fully susceptible population, ranges from 4 to 7, underscoring its moderate to high infectivity and potential for rapid spread in unvaccinated or low-immunity groups, especially crowded environments like schools, universities, or military barracks where prolonged close contact facilitates droplet exchange.^[62] ^[63] This R₀ estimate derives from pre-vaccination epidemiological data and modeling, highlighting the virus's reliance on human-to-human respiratory pathways without environmental reservoirs amplifying spread.^[64]

Immunology

Natural immune response

Upon natural infection with mumps virus, the innate immune response involves initial recognition by pattern recognition receptors, leading to interferon production and activation of natural killer cells, which limit early viral replication in epithelial cells of the respiratory tract.^[60] The adaptive immune response features humoral seroconversion, with mumps-specific IgM antibodies typically detectable within 2-3 weeks post-infection, coinciding with symptom onset after the 12-25 day incubation period, followed by IgG appearance that persists lifelong in over 95% of cases.^[3]^[65] This durable humoral immunity, evidenced by sustained neutralizing antibody titers in longitudinal serological surveys of pre-vaccine era cohorts, correlates with protection against severe disease.^[66] Cellular immunity plays a critical role in viral clearance, with CD8+ cytotoxic T cells targeting mumps virus epitopes on infected cells, particularly in lymphoid tissues like the parotid gland, while CD4+ T helper cells support B cell maturation and sustain memory responses.^[67]^[68] Studies of naturally infected individuals demonstrate robust, polyfunctional T cell responses persisting for years, contributing to resolution of viremia and parotitis.^[69] Secretory IgA antibodies at mucosal surfaces, induced post-infection, neutralize virus in the upper respiratory tract, impeding initial attachment and reinfection.^[60] Cohort studies from pre-vaccination periods report reinfection rates below 1%, attributable to this multifaceted memory response encompassing high-avidity IgG, T cell vigilance, and mucosal barriers.^[27]^[70]

Vaccine-induced immunity: mechanisms and duration

The live attenuated mumps vaccine, typically the Jeryl Lynn strain administered subcutaneously as part of the MMR formulation, stimulates both humoral and cellular immune responses by replicating locally in muscle tissue and draining lymph nodes, thereby mimicking aspects of natural infection without causing disease. It primarily induces neutralizing IgG antibodies that target viral surface glycoproteins, inhibiting viral entry into host cells, alongside memory T-cell responses including CD4+ helper T cells producing IFN-γ and CD8+ cytotoxic T cells for viral clearance.^[71]^[72] However, unlike natural mumps infection, which elicits robust mucosal IgA secretion at respiratory and salivary sites of entry, vaccine-induced immunity generates comparatively weaker secretory antibody responses due to the parenteral route of administration, potentially allowing greater viral replication in the upper respiratory tract upon exposure.^[73] Empirical estimates of two-dose vaccine effectiveness against clinical mumps disease range from 86% to 88% in controlled studies, though real-world outbreak investigations often report lower figures (64-92%) attributable to factors like strain mismatch and host variability.^[74]^[75] Protection against infection itself is inferior, estimated at around 78% or less, as evidenced by breakthrough cases and outbreaks in highly vaccinated cohorts where virus replication occurs subclinically.^[76] This lack of sterilizing immunity permits asymptomatic infection and, in some documented instances, viral shedding from vaccinated individuals, facilitating transmission chains as seen in a 2020 multistate outbreak traced to an asymptomatic, two-dose-vaccinated index case with extensive close contacts.^[77]^[78] Serological surveys reveal waning vaccine-induced immunity, with geometric mean antibody titers declining significantly 15-25 years post-vaccination; for instance, models from U.S. outbreak data estimate average protection duration of 27 years (95% CI: 16-51), after which seropositivity drops below protective thresholds in a substantial fraction of recipients.^[28]^[6] This transience is corroborated by longitudinal assays showing reduced plaque reduction neutralization titers over decades, correlating with increased outbreak risk in young adults vaccinated in infancy, despite initial robust seroconversion rates exceeding 95% after two doses.^[79]^[80] Cellular immunity persists longer but insufficiently compensates for humoral decline, as T-cell responses, while detectable, do not fully prevent reinfection in waning scenarios.^[71]

Diagnosis

Clinical evaluation

Clinical evaluation of mumps relies on recognizing characteristic symptoms, particularly acute onset of parotitis, in the context of potential exposure. The typical presentation includes a prodromal phase of low-grade fever, malaise, headache, myalgia, and anorexia lasting 1-2 days, followed by painful swelling of one or both parotid glands, which peaks within 1-3 days and resolves over about 5 days.^[1] Parotitis occurs in over 70% of symptomatic cases, with initial unilateral involvement in 20-30% that often progresses to bilateral swelling.^[81] A diagnostic triad of parotitis, fever, and recent exposure history raises high suspicion, especially in unvaccinated individuals or during outbreaks.^[2] Differential diagnosis for parotitis includes bacterial infections such as Staphylococcus aureus suppurative parotitis, which presents with more severe pain, purulent discharge from Stensen's duct, and systemic toxicity; sialadenitis due to salivary stones or dehydration; and noninfectious causes like lymphoma or Sjögren's syndrome, which may feature chronic or asymmetric swelling without viral prodrome.^[39]^[82] Other viral etiologies, including parainfluenza, influenza, Epstein-Barr virus, and coxsackievirus, can mimic mumps but typically lack the prolonged glandular swelling or epidemiologic link.^[83] Clinical suspicion is heightened in settings of low vaccination coverage, as mumps incidence correlates with immunity gaps.^[1] For surveillance purposes, the CDC defines a suspected mumps case as acute parotitis or other salivary gland swelling lasting at least 2 days, or a mumps-associated complication such as orchitis or pancreatitis, without alternative explanation.^[84] The WHO-aligned criteria emphasize fever with sudden unilateral or bilateral tender parotid swelling without apparent cause, facilitating outbreak detection independent of laboratory confirmation.^[85] These definitions prioritize clinical features to guide public health response while acknowledging that up to 30% of infections may be subclinical, complicating reliance on symptoms alone.^[3]

Laboratory methods

Real-time reverse transcription polymerase chain reaction (rRT-PCR) assays targeting conserved regions of the mumps virus genome, such as the nucleoprotein or small hydrophobic protein genes, serve as the preferred laboratory method for confirming acute mumps infection due to their high sensitivity and specificity in detecting viral RNA.^[86] Buccal swabs, collected by massaging the parotid glands and swabbing the Stensen's duct orifice, yield the highest detection rates when obtained within the first 3 days of parotitis onset, with positivity rates exceeding 90% in confirmed cases tested by multiple methods.^[87] Oropharyngeal or throat swabs provide acceptable alternatives, though slightly lower yields compared to buccal samples, while urine and cerebrospinal fluid can be used in specific complications like orchitis or meningitis.^[88] These assays outperform viral culture, which, despite being historically confirmatory, is less sensitive, more labor-intensive, and slower, with rRT-PCR showing 100% correlation to culture positives in validation studies.^[89] Serologic testing detects mumps-specific antibodies but is secondary to molecular methods for acute diagnosis, as immunoglobulin M (IgM) antibodies may not appear until 2-3 days post-onset and can persist or yield false positives from cross-reactivity or vaccination.^[90] Detection of IgM in serum collected soon after symptom onset supports diagnosis, particularly in unvaccinated individuals, but sensitivity drops in vaccinated populations; a fourfold rise in immunoglobulin G (IgG) between acute and convalescent sera (collected 2-3 weeks apart) provides stronger confirmation.^[2] IgG avidity testing differentiates recent primary infection (low avidity) from past exposure or vaccination (high avidity), enhancing specificity when paired with molecular results.^[90] Oral fluid samples enable non-invasive surveillance but are less reliable for individual diagnosis due to variable antibody levels.^[86] Genotyping via sequencing of the short fragment of the small hydrophobic (SH) gene from rRT-PCR-positive specimens facilitates molecular epidemiology, identifying circulating strains such as genotype G, which predominates in recent outbreaks, and tracing transmission chains during investigations.^[48] This approach, performed on amplicons from buccal or throat swabs, supports public health responses by distinguishing vaccine-related from wild-type viruses but is not routine for clinical diagnosis.^[91]

Prevention

Vaccination: efficacy and schedules

The mumps vaccine is administered as part of the combined measles-mumps-rubella (MMR) vaccine or the measles-mumps-rubella-varicella (MMR-V) vaccine for children. The standard schedule recommended by the U.S. Centers for Disease Control and Prevention (CDC) consists of two doses: the first dose at 12 through 15 months of age and the second dose at 4 through 6 years of age, prior to school entry.^[92] This regimen aims to provide long-term protection against mumps virus infection, though monovalent mumps vaccines are rarely used outside research or specific shortage contexts.^[92] Two doses of MMR vaccine confer approximately 86% effectiveness against mumps illness, with estimates ranging from 32% to 95% across studies accounting for genotype-specific protection and surveillance data.^[92] A Cochrane systematic review of randomized and observational data indicates that two doses reduce the risk of mumps from 7.4% in unvaccinated individuals to about 1%, corresponding to an 86% risk reduction.^[93] However, real-world effectiveness appears lower in outbreak settings due to waning immunity over time, with breakthrough infections occurring in 10-20% of two-dose recipients, particularly among young adults where antibody levels decline 10-20 years post-vaccination.^[94] Secondary attack rates in household or close-contact exposures among two-dose vaccinated individuals range from 2.2% to 7.7%, influenced by viral strain and exposure intensity.^[76] During mumps outbreaks, a third dose of MMR is recommended for at-risk populations, such as close contacts or high-exposure groups like university students, to boost waning immunity.^[92] Observational data from a 2016-2017 outbreak showed that a third dose reduced mumps risk by 78% compared to two doses alone within 28 days post-vaccination.^[5] Mathematical modeling from 2024 indicates that early third-dose campaigns during outbreaks can interrupt transmission chains effectively, even in populations with high two-dose coverage, by elevating short-term antibody titers and reducing outbreak peaks by up to 50% in simulated scenarios.^[95] Despite these benefits, third doses do not restore lifelong sterilizing immunity and are not part of routine schedules due to logistical challenges and evidence of eventual waning.^[95]

Public health interventions

Public health interventions for mumps emphasize isolation of confirmed or suspected cases, contact tracing, and enhanced surveillance to limit transmission, particularly in community and institutional settings where outbreaks can occur rapidly due to the virus's contagiousness via respiratory droplets.^[96] Individuals with parotitis, the hallmark symptom, are recommended to self-isolate for 5 days following onset, as this aligns with the period of peak infectiousness, during which viral shedding is highest.^[97] For those without parotitis but with other symptoms suggestive of mumps, exclusion from work, school, or public spaces for 5 days after symptom onset is advised to prevent potential spread.^[98] Contact tracing focuses on exposures from 2 days before to 5 days after parotitis onset in index cases, enabling identification of close contacts—defined as prolonged face-to-face interactions or shared spaces—for symptom monitoring.^[99] Quarantine of contacts is not routinely mandated outside of high-risk outbreaks or congregate settings like universities, where unimmunized or exposed individuals may be required to isolate pending symptom development or lab confirmation, with daily monitoring from day 10 to 25 post-exposure.^[100] ^[101] In outbreak scenarios, such as campuses, targeted exclusions of susceptible persons and temporary restrictions on group activities have been implemented to curb chains of transmission.^[102] Hygiene promotion, including frequent handwashing, respiratory etiquette, and improved ventilation in shared spaces, supplements these measures by reducing droplet dissemination, though evidence for mumps-specific impact remains supportive rather than primary due to the virus's airborne persistence.^[103] School or facility closures are rarely recommended, with responses instead prioritizing case exclusions, enhanced cleaning of surfaces, and cohorting of unaffected groups to maintain operations while containing spread.^[104] Surveillance systems, such as the CDC's National Notifiable Diseases Surveillance System (NNDSS), facilitate early detection by requiring mandatory reporting of suspected and confirmed cases from healthcare providers and laboratories across all U.S. states, enabling rapid outbreak investigation and resource allocation.^[27] ^[105] This framework supports real-time data aggregation, with weekly provisional reports aiding in tracking incidence trends and informing targeted interventions.^[106]

Herd immunity thresholds and challenges

The herd immunity threshold for mumps, derived from its basic reproduction number (R0) estimated at 4–7, theoretically ranges from 75% to 88% population immunity to interrupt transmission chains.^[62]^[107] However, empirical data indicate that this threshold is insufficient in vaccinated populations, where outbreaks occur despite coverage exceeding 90%, necessitating effective immunity levels closer to 97% to account for heterogeneous mixing and incomplete protection.^[108] Waning vaccine-induced immunity, with protection declining on average 27 years post-last dose, undermines long-term herd effects, as antibody levels drop below protective thresholds in young adults, enabling breakthrough infections that sustain transmission.^[28]^[6] The mumps component of MMR vaccine provides non-sterilizing immunity, reducing severe disease but permitting asymptomatic or mild cases—estimated at 20–30% of infections—that facilitate onward spread, particularly in close-contact settings like universities.^[77]^[109] This is evidenced by 75 U.S. university outbreaks from 2016–2017 and a 2019 Temple University cluster, where two-dose coverage exceeded 90% yet failed to prevent resurgence due to these gaps.^[110]^[111] Additional challenges include international travel seeding outbreaks with wild-type strains mismatched to vaccine genotypes, and primary vaccine failure in 5–10% of recipients, which collectively erode population-level barriers even at high nominal coverage.^[35] Modeling supports routine third-dose MMR administration during outbreaks to restore short-term immunity and avert escalation, outperforming boosters alone by addressing both waning and incomplete initial responses.^[95]^[112] Despite these interventions, sustained herd immunity remains elusive without strategies targeting lifelong protection, as resurgences persist in cohorts with >90% two-dose vaccination.^[113]^[108]

Treatment and Management

Supportive care

Mumps infection is typically self-limiting and resolves without specific antiviral therapy, with management focused on alleviating symptoms and preventing secondary complications through supportive measures.^[1]^[2] Patients are advised to rest and maintain adequate hydration by consuming plenty of fluids to counteract fever-induced dehydration and support salivary gland function.^[114]^[115] Symptomatic relief includes administration of analgesics such as acetaminophen or ibuprofen to reduce fever, headache, and discomfort from parotitis or orchitis; aspirin should be avoided in children due to the risk of Reye's syndrome.^[114]^[115] A soft diet consisting of easily chewable foods is recommended to minimize pain during mastication, while warm or cold compresses applied to the affected parotid glands can provide localized relief from swelling.^[114]^[115] No routine antiviral agents are approved or recommended, as agents like ribavirin have shown only in vitro inhibitory effects against mumps virus replication without established clinical efficacy in human cases.^[2]^[116] Hospitalization is rare, occurring in fewer than 5% of cases, and is generally reserved for severe dehydration, significant complications such as orchitis requiring supportive intervention, or management of central nervous system involvement.^[117]^[2]

Prognosis

Most individuals with mumps achieve full recovery within 2 weeks, with symptoms such as parotitis, fever, and malaise resolving spontaneously in over 95% of uncomplicated cases.^[118] Complications arise in fewer than 10% of infections overall, primarily manifesting as orchitis (in up to 25-50% of postpubertal males), oophoritis, aseptic meningitis, or pancreatitis, and these are generally self-resolving without intervention beyond supportive care.^[2]^[119] Permanent sequelae remain rare, though testicular atrophy develops in 30-50% of orchitis-affected testicles, occasionally resulting in subfertility or infertility, particularly with bilateral involvement; fertility impairment is documented in approximately 13% of such patients.^[43] Overall mortality is exceedingly low at less than 0.01% (1-3 deaths per 10,000 cases), typically linked to encephalitis or myocarditis in vulnerable populations.^[120] Natural infection with wild-type mumps virus induces robust, lifelong immunity in the vast majority of cases, conferring sterilizing protection against reinfection, in contrast to vaccine-induced responses that may wane over decades.^[21]^[121]

Epidemiology

Global and historical trends

Prior to the introduction of the mumps vaccine in 1967, the disease was a ubiquitous childhood infection worldwide, with nearly universal exposure by adolescence in unvaccinated populations. In the United States, approximately 162,000 cases were reported annually during the mid-20th century, though underreporting likely meant actual incidence was substantially higher.^[122] Globally, pre-vaccine estimates suggest millions of cases occurred yearly, reflecting endemic circulation driven by high susceptibility in children and lack of immunity in adults.^[3] Following licensure of the live attenuated mumps vaccine in 1967 and its integration into routine immunization programs, such as the combined measles-mumps-rubella (MMR) vaccine in 1971, reported cases declined by more than 99% in the United States and other high-vaccination-coverage nations by the 1980s.^[32] ^[19] Similar reductions occurred in countries achieving high two-dose MMR coverage, transforming mumps from a routine childhood illness to a rare event in vaccinated cohorts.^[2] In regions with low vaccine uptake, such as parts of sub-Saharan Africa and South Asia where mumps vaccine introduction lags and coverage remains below 70% for the first dose, incidence persists at elevated levels, with outbreaks reported annually.^[123] By contrast, as of 2023, high-income countries maintained stable low endemicity, with the United States reporting 429 cases and the European Union/EEA averaging 0.7 cases per 100,000 population.^[122] ^[124] The World Health Organization has not set a global elimination target for mumps akin to measles, citing challenges from waning vaccine-induced immunity over 15-30 years, which sustains low-level transmission despite high initial coverage.^[28] ^[27]

Factors driving resurgences

Waning of vaccine-derived immunity represents the primary empirical driver of mumps resurgences in highly vaccinated populations during the 2010s and 2020s. Mathematical modeling of U.S. outbreak data indicates that protective immunity from the measles-mumps-rubella (MMR) vaccine declines with an average duration of 27 years (95% confidence interval: 16–51 years) after the last dose, leading to secondary vaccine failure where initial protection erodes over time despite two doses.^[28] This waning is evidenced by serological studies showing decreased mumps-specific antibody levels in young adults vaccinated 15–20 years prior, correlating with increased outbreak vulnerability.^[6] Causal analyses prioritize this factor over vaccine hesitancy, as resurgences have predominantly occurred in settings with vaccination coverage exceeding 90%, such as universities and close-knit communities.^[34] Outbreak investigations from this period further substantiate waning immunity's role, with CDC data revealing that over 80% of cases—and in some instances up to 94%—involved individuals who had received two MMR doses.^[32] ^[125] For example, multistate outbreaks between 2015 and 2019, totaling thousands of cases, primarily affected vaccinated adolescents and young adults in dense congregate environments like college campuses and dormitories, where sustained close contact facilitates transmission despite partial immunity.^[126] Low rates of adult booster vaccination exacerbate this, as routine schedules do not include third doses, allowing immunity thresholds to drop below critical levels in aging cohorts.^[35] Genotypic shifts in circulating mumps strains, such as the emergence of genotype G, play a secondary and minor role compared to waning, with evidence indicating limited immune escape due to vaccine strain homology and no consistent association with outbreak scale across analyses.^[34] These factors collectively explain resurgences without invoking primary vaccine failure or broad hesitancy, as outbreak patterns align with predictable immunological decay rather than coverage gaps.^[31]

Current outbreaks and demographic patterns

In 2023, the European Union and European Economic Area reported 2,963 laboratory-confirmed mumps cases across 27 member states, yielding an incidence rate of 0.7 cases per 100,000 population, with Poland accounting for the highest national total.^[127] Outbreaks in the United States continue to occur predominantly in close-contact environments such as universities, schools, and correctional facilities, reflecting patterns observed through 2025.^[32] Demographic data indicate that mumps incidence peaks among adolescents and young adults, particularly those aged 18-24 years, coinciding with waning vaccine-induced immunity around college entry age; for instance, U.S. rates reached 4.54 cases per 100,000 in this group during peak years of 2018-2020, a trend persisting into recent surveillance.^[128] Males experience slightly higher overall case rates, with ratios ranging from 1.5:1 to 1.7:1 male-to-female in various studies, and they face elevated risks for complications like orchitis.^[129] Clusters often emerge in communities with international travel links or dense populations, exacerbating transmission among partially immune young adults.^[124] Primary vaccine failure contributes to susceptibility gaps, affecting approximately 5-15% of recipients after two doses of strains like Jeryl Lynn, with higher rates observed against certain circulating genotypes; secondary waning of immunity over 10-15 years further drives outbreaks in vaccinated cohorts.^[130]^[34] These patterns underscore vulnerabilities in high-density settings where even low failure rates enable sustained chains of transmission.^[131]

References

[1]
Clinical Overview of Mumps - CDC
Jan 17, 2025 · Mumps is a viral illness caused by a paramyxovirus, a member of the Rubulavirus family. Mumps usually involves pain, tenderness, and swelling in one or both ...
[2]
Mumps - StatPearls - NCBI Bookshelf
May 1, 2024 · Mumps is caused by the rubulavirus, which belongs to the Paramyxoviridae family. ... Mumps is caused by a single-stranded RNA paramyxovirus.
[3]
Chapter 15: Mumps | Pink Book - CDC
May 1, 2024 · Mumps virus is a paramyxovirus in the same group as parainfluenza and Newcastle disease viruses, which produce antibodies that cross-react with ...
[4]
About Mumps - CDC
Jul 11, 2025 · Mumps is a contagious disease caused by a virus that affects the salivary glands. Mumps is still a common disease in many countries, so it's important to get ...
[5]
Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak ...
Sep 7, 2017 · Waning immunity has been shown in several previous studies, through a decrease in mumps antibody titers years after vaccination, a decrease in ...
[6]
Decreased humoral immunity to mumps in young adults ... - PNAS
Sep 3, 2019 · Mumps PRN titers and IgG antibodies appear to wane with time even though there is a high rate of seroconversion after the first and second doses ...
[7]
Mumps - Etymology, Origin & Meaning
Mumps, from Dutch "mompen" (to mumble) via English "mump" (to whine), originated c.1600; it means a contagious disease causing inflammation of facial glands ...
[8]
mumps, n.¹ meanings, etymology and more | Oxford English Dictionary
OED's earliest evidence for mumps is from 1576, in the writing of George Whetstone, writer. mumps is perhaps formed within English, by clipping or shortening.Missing: disease | Show results with:disease
[9]
parotitis - Wiktionary, the free dictionary
Etymology. Learned borrowing from Ancient Greek παρωτῖτις (parōtîtis, “(disease of the) parotid gland”), from παρωτίς (parōtís, “gland behind the ear”). By ...English · Noun
[10]
parotitis, n. meanings, etymology and more | Oxford English Dictionary
The earliest known use of the noun parotitis is in the late 1700s. OED's earliest evidence for parotitis is from 1796, in the writing of Erasmus Darwin, ...
[11]
Molecular biology, pathogenesis and pathology of mumps virus - PMC
Mumps is characterized by painful inflammatory symptoms, such as parotitis and orchitis. The virus is highly neurotropic, with laboratory evidence of central ...
[12]
Reemergence of mumps - PMC - NIH
However, isolation and culture of the virus was only possible in 1945, and vaccination was first licensed in 1967. Without routine immunization, the incidence ...
[13]
[PDF] The Thasian epidemic of mumps during the 5th century BC - InfezMed
Hippocrates' observation on the Thasian mumps (epidemic parotitis), gave us the first written detailed description of the disease, which still constitutes a ...Missing: recognition Biblical<|separator|>
[14]
Mumps epidemic dynamics in the United States before vaccination ...
During that time, 239,230 mumps cases were reported in 70 cities. Larger cities reported annual epidemics and smaller cities reported intermittent, sporadic ...
[15]
Mumps - an overview | ScienceDirect Topics
“Mumps” was first described as a disease in the 5th century BC, and was named in a Scottish report published in 1790 by a scientist who used the name given to ...
[16]
AN INVESTIGATION OF THE ETIOLOGY OF MUMPS - PubMed
AN INVESTIGATION OF THE ETIOLOGY OF MUMPS. J Exp Med. 1934 Jan 1;59(1):1-19. doi: 10.1084/jem.59.1.1. Authors. C D Johnson , E W Goodpasture. Affiliation. 1 ...Missing: isolation | Show results with:isolation
[17]
AN INVESTIGATION OF THE ETIOLOGY OF MUMPS - PMC - NIH
From four out of six specimens of saliva from six cases of mumps in the early stages of the disease, a filterable cytotropic virus has been obtained which ...Missing: isolation | Show results with:isolation
[18]
Maurice Hilleman: Creator of Vaccines That Changed the World - PMC
In 1963, Hilleman isolated the mumps virus from a throat swab from his five-year old daughter and developed a new vaccine, which was licensed in 1967, and was ...
[19]
Mumps | History of Vaccines
Mumps is caused by a virus from the genus Rubulavirus. Its symptoms include low-grade fever, respiratory problems, and most notably swelling of the salivary ...Missing: etymology | Show results with:etymology
[20]
Mumps Surveillance -- United States, 1988-1993 - CDC
Mumps vaccine was licensed in the United States in December 1967, and the Advisory Committee on Immunization Practices (ACIP) recommended that its use be ...Missing: date | Show results with:date
[21]
Mumps: Practice Essentials, Background, Etiology
The illness is caused by the RNA virus, Rubulavirus. Rubulavirus is within the genus Paramyxovirus and is a member of the family Paramyxoviridae.
[22]
What is the history of Mumps vaccine use in America?
Feb 5, 2023 · In 1971, Mumpsvax was combined with the measles and rubella vaccine to become the MMR vaccine.Missing: date monovalent
[23]
History of Mumps - National Vaccine Information Center (NVIC)
Jan 22, 2023 · In 1934, researchers determined that the mumps virus that was present in the saliva could be spread from an infected individual to rhesus ...<|control11|><|separator|>
[24]
Epidemiologic Notes and Reports Mumps -- United States, 1985-1986
In 1985, 2,982 cases of mumps were reported in the United States, representing an annual incidence rate of 1.2 cases/100,000 population (Table 6).
[25]
An assessment of mumps vaccine effectiveness by dose during an ...
Clinical trials have reported vaccine efficacy of approximately 95% after one dose of mumps vaccine under controlled conditions, although estimates of vaccine ...
[26]
Vaccine Effectiveness Estimates, 2004–2005 Mumps Outbreak ...
In early clinical trials, the efficacy of a single dose of mumps vaccine was >95%, but estimates of the effectiveness in field evaluations have been 62%–85% (8 ...Missing: one | Show results with:one
[27]
Chapter 9: Mumps | Manual for the Surveillance of Vaccine ... - CDC
Jun 18, 2025 · Mumps is an acute viral illness caused by a paramyxovirus and typically presents as swelling of the parotid (parotitis) or other salivary gland.
[28]
Vaccine waning and mumps re-emergence in the United States - PMC
Whereas over 90% of US-born children experienced mumps infections by age 20 in the pre-vaccine era (3), incidence declined substantially after licensure of a ...
[29]
Multistate Outbreak of Mumps --- United States, January 1 - CDC
May 18, 2006 · The current multistate mumps outbreak, with 2,597 cases reported through May 2, 2006 ... college with higher 2-dose vaccination coverage. To ...
[30]
Mumps vaccination coverage and vaccine effectiveness in a large ...
Jul 4, 2008 · Two-dose mumps vaccination coverage was 90% both for the student population (2128/2363) and case-students (97/108). Two-dose vaccine effectiveness was 76-88%.
[31]
Recent Resurgence of Mumps in the United States
Apr 10, 2008 · The 2006 outbreaks on college campuses resemble those among schoolchildren who received one dose of vaccine during the 1980s,4,20–22 which ...
[32]
Mumps Cases and Outbreaks - CDC
Sep 12, 2025 · However, reported U.S. mumps cases and outbreaks increased since 2006. Most of these cases were in young adults and vaccinated people. Large ...Key Points · Mumps Outbreaks Still Happen · Mumps Cases
[33]
Mumps | Johns Hopkins ABX Guide
Feb 18, 2023 · ... U.S. cases (2016-2019): 2251-6369 reported cases per year. In 2022, 322 reported cases reflective of enhanced vaccine efforts. Increased ...<|separator|>
[34]
Disentangling the causes of mumps reemergence in the United States
Jan 9, 2023 · We found waning of vaccine-derived immunity to be the most likely reason for mumps reemergence in the early 21st century US.Missing: 1968 | Show results with:1968
[35]
Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic ...
In addition, mumps also affected adults in close-contact settings, such as U.S. military troops on active duty during World War I (122). Since vaccine ...
[36]
Recent Mumps Outbreaks in Vaccinated Populations - NIH
... vaccine and outbreak strains may allow for vaccine escape (20, 45). Indeed, viruses isolated from recent outbreaks cluster into genotype groupings distinct ...
[37]
MMR vaccination and genetic diversity of mumps virus, 2007–2011 ...
Nov 9, 2019 · Antigenic differences between vaccine and circulating wild-type mumps viruses decreases neutralization capacity of vaccine-induced antibodies.
[38]
News & Views — Mumps: "Fast Facts" for Healthcare Providers
Aug 26, 2025 · During outbreaks, public health authorities may recommend a third dose of vaccine to people in high-risk groups. For example, if there is an ...Missing: 2023-2025 | Show results with:2023-2025
[39]
Clinical Features of Mumps - CDC
Jun 5, 2024 · Nonspecific prodromal symptoms may precede parotitis by several days, including: Low-grade fever which may last 3 to 4 days; Myalgia; Anorexia ...
[40]
Factsheet about mumps - ECDC
Nov 28, 2023 · Complications include sensorineuronal deafness, oligospermia, subfertility (rarely) and occasionally death from encephalitis. In the pre-vaccine ...Missing: empirical | Show results with:empirical
[41]
Recommendations of the Immunization Practices Advisory ... - CDC
A killed mumps virus vaccine was licensed for use in the United States from 1950 through 1978. This vaccine induced antibody, but the immunity was transient.
[42]
Mumps Orchitis: Clinical Aspects and Mechanisms - PMC
Mar 18, 2021 · Approximately 30% of mumps orchitis in post pubertal males suffer from infertility or subfertility (3). ... The increasing incidence of mumps ...
[43]
Mumps orchitis - PMC - NIH
Mumps orchitis rarely leads to sterility but it may contribute to subfertility. It can also can lead to oligospermia, azoospermia, and asthenospermia (defects ...
[44]
Mumps Complications and Effects of Mumps Vaccination, England ...
Mumps meningitis has been reported in 1%–10%, mumps pancreatitis in 4%, and mumps oophoritis in 5% of persons with mumps (3,25,26).<|separator|>
[45]
Mumps | Red Book Online | American Academy of Pediatrics
Uncommon complications include oophoritis, pancreatitis, encephalitis, hearing loss (either transient or permanent), arthritis, thyroiditis, mastitis, ...
[46]
Unique Tropism and Entry Mechanism of Mumps Virus - PMC
MuV is an enveloped, non-segmented, negative-stranded RNA virus of the genus Orthorubulavirus and family Paramyxoviridae. Its genome contains 15,384 nucleotides ...
[47]
Changes in Mumps Virus Gene Sequence Associated with ...
Mumps virus is a 15.3-kb enveloped, nonsegmented, negative-strand RNA virus in the Paramyxoviridae family. The mumps virus genome organization is 3′ NP-P-M-F-SH ...
[48]
Genetic Analysis of Mumps Viruses - CDC
Jun 10, 2024 · Mumps strains are assigned to 1 of 12 genotypes (genetic constitutions) based on the sequences of the gene coding for the short hydrophobic (SH) protein.Missing: predominant | Show results with:predominant
[49]
[PDF] Mumps Virus Pathogenesis Clinical Features
Outbreaks of mumps have been reported among military personnel as recently as 1986. Mumps virus is a paramyxovirus in the same group as parainfluenza and ...
[50]
Structural studies on the authentic mumps virus nucleocapsid ...
In this paper we solved an 18-Å–resolution structure of the authentic MuV NC using cryo-electron microscopy. We also observed the effects of phosphoprotein (P) ...Abstract · Results · Discussion
[51]
Structural plasticity of mumps virus nucleocapsids with cryo-EM ...
Jul 2, 2021 · Here, we report two MuV nucleoprotein-RNA rings with 13 and 14 protomers, one stacked-ring filament and two nucleocapsids with distinct helical ...Results · Muv N-Rna Rings In Different... · Muv N-Rna Filaments In...
[52]
Structures of the mumps virus polymerase complex via cryo-electron ...
May 17, 2024 · The mumps virus, which belongs to the family Paramyxoviridae ... proteins are required for defective interfering particle genome replication in ...<|separator|>
[53]
Paramyxoviruses - Medical Microbiology - NCBI Bookshelf - NIH
Mumps virus belongs to the genus Paramyxovirus and exhibits most characteristics of the Paramyxoviridae. It occurs only in a single serotype and shares minor ...General Concepts · Introduction · Parainfluenza Viruses · Respiratory Syncytial Virus
[54]
ICTV Virus Taxonomy Profile: Paramyxoviridae - PMC - NIH
Mumps virus and parainfluenza virus 5 have an ATU encoding an SH protein between the F and RBP genes.
[55]
Structural and Functional Characterization of the Mumps Virus ...
The phosphoprotein (P) is virally encoded by the Rhabdoviridae and Paramyxoviridae in the order Mononegavirales. P is a self-associated oligomer and forms ...
[56]
Family: Paramyxoviridae - ICTV
The family Paramyxoviridae consists of large enveloped RNA viruses infecting mammals and birds, or in some cases reptiles and fish (Table 1. Paramyxoviridae).
[57]
Immunological Relationships between Mumps Virus and ...
Sep 1, 1986 · The different cross-reactions found show that Sendai virus is antigenically related to both mumps virus and parainfluenza type 3 virus. In ...
[58]
Paramyxoviridae - an overview | ScienceDirect Topics
The mumps genome contains seven parallel linked transcription units, including: nucleo (N), V/P/I, matrix (M), fusion (F) (Griffin), small hydrophobic (SH) ( ...
[59]
Alveolar macrophages are early targets of mumps virus - PNAS
Following infection, MuV is thought to first replicate in the upper respiratory epithelium before local lymphatic infection and eventually viremia (20). While ...
[60]
Mumps virus pathogenesis: Insights and knowledge gaps - PMC - NIH
Jul 25, 2016 · Migrating mumps virus-infected T cells could facilitate spread from the respiratory tract to other sites of the body and might therefore play an ...
[61]
Detection of RNA of Mumps Virus during an Outbreak in a ...
Isolation has been recommended for 4 or 9 days (1, 5, 11, 13), based on data showing viral shedding up to 9 days after symptom onset.
[62]
Seroprevalence of mumps in healthcare workers in South Korea
The basic reproduction number of mumps is 4–7; therefore, the herd immunity of mumps must be maintained above 75%–86% to decrease its incidence and eradicate ...Missing: R0 | Show results with:R0
[63]
Mumps and the UK epidemic 2005 - PMC - PubMed Central
The number of secondary cases of infection expected to result from an index case of mumps in a fully susceptible population (R0 or basic reproduction number) is ...
[64]
The pre-vaccination epidemiology of measles, mumps and rubella in ...
Key epidemiological parameters, such as the age-specific force of infection and the basic reproduction number (R0) are estimated from case notification or ...
[65]
Mumps | Red Book Online | American Academy of Pediatrics
Testing for mumps-specific immunoglobulin (Ig) M antibody, IgG seroconversion, or a significant increase between acute and convalescent IgG antibody titer ...
[66]
Remembering Mumps - PMC - NIH
The mumps virus belongs to the family of paramyxoviruses. It has a single-strand, nonsegmented, negative-sense RNA genome and is spread by the respiratory ...<|control11|><|separator|>
[67]
The Human CD4+ T Cell Response against Mumps Virus Targets a ...
Mar 5, 2019 · The role of CD4+ T cells in viral infections is evident, as they provide help to B cells for an enhanced antibody response, and CD4+ T cells ...
[68]
Identification of Naturally Processed Mumps Virus Epitopes by Mass ...
Sep 27, 2019 · In a recent study, we observed a dominant polyfunctional CD8+ T-cell response after natural mumps virus (MuV) infection that was not present ...
[69]
Novel mumps virus epitopes reveal robust cytotoxic T cell responses ...
Jul 1, 2021 · Following respiratory virus infection, a robust CD8 + T cell response can be induced to mediate viral clearance. The question is whether ...
[70]
Mumps | health.vic.gov.au
Feb 25, 2025 · Cold or warm packs applied to swollen glands may provide relief. Simple analgesic agents, such as paracetamol may help to reduce fever or pain.<|control11|><|separator|>
[71]
Immune Responses to Mumps Vaccine in Adults Who Were ... - NIH
In this study, we showed that mumps vaccination induced strong memory T cell immunity, as demonstrated by T cell proliferation and IFN-γ production in adults ...Missing: mucosal | Show results with:mucosal
[72]
Mumps virus-specific immune response outcomes and sex-based ...
Evidence suggests that mumps vaccine-induced humoral immunity wanes over time. Relatively few studies have examined cell-mediated immunity or reported on sex- ...Missing: mucosal | Show results with:mucosal
[73]
Correlates of Protection Induced by Vaccination - ASM Journals
Jul 1, 2010 · T-cell responses to mumps vaccine have been demonstrated, but their protective effect is unknown. The need to define a correlate of immunity to ...Bacteria That Replicate... · Viruses Transmitted By... · Viruses Replicating Only On...<|separator|>
[74]
[PDF] Mumps vaccines; studies on immune responses, efficacy and ...
We found no evidence to indicate that waning immunity (secondary vaccine failure) contributed significantly to this outbreak. A second dose of mumps vaccine, as ...
[75]
Mumps vaccine effectiveness and risk factors for disease in ...
Mumps outbreaks have been reported among vaccinated populations, and declining mumps vaccine effectiveness (VE) has been suggested as one possible cause.<|separator|>
[76]
Mumps Vaccine Performance among University Students during a ...
A Belgian study involving predominantly school-aged children who had received 1 dose of vaccine found that the odds of having mumps increased 27% per 1-year ...
[77]
Multistate Mumps Outbreak Originating from Asymptomatic ... - CDC
Jun 5, 2020 · A multistate outbreak followed contact with an asymptomatic, fully vaccinated index patient who reported extensive social interactions at a wedding.Missing: sterilizing | Show results with:sterilizing
[78]
Mumps Outbreaks in Vaccinated Populations—Is It Time to Re ...
Mumps-specific antibodies have been detected 1–2 years post-vaccination and without substantial decline for 8 years after mumps vaccination, with the ...
[79]
Decade-long protection of the mumps vaccine: Insights from a large ...
Jun 3, 2025 · A time-lapse assay of IgG antibodies indicated that the mumps vaccine provided protection for one decade, which highlights that booster ...
[80]
Long-term immunogenicity of measles, mumps and rubella ...
Aug 23, 2019 · Moreover, a very recent model based on a meta-analysis suggested that the average waning of immunity against mumps occurs 27 years (95% ...
[81]
Mumps | Pediatrics In Review - AAP Publications
Nov 1, 2023 · After the prodromal period, unilateral (20%–30%) or bilateral (70%–80%) parotid swelling becomes apparent (Fig 1), obscuring the angle of the ...
[82]
Mumps Differential Diagnoses - Medscape Reference
Feb 6, 2025 · Conditions to be considered in the differential diagnosis for mumps include the following: ... Parotitis (different etiologies). Mixed ...
[83]
Parotitis - StatPearls - NCBI Bookshelf - NIH
Jun 23, 2025 · Parotitis, or inflammation of the parotid glands, is the most common inflammatory condition affecting the major salivary glands.Missing: etymology | Show results with:etymology
[84]
Mumps 2024 Case Definition | CDC
Mumps is caused by infection with a paramyxovirus and is transmitted person to person through direct contact with saliva or respiratory droplets.
[85]
Case Definition - Health Protection Surveillance Centre
Any person with fever AND sudden onset of unilateral or bilateral tender swelling of the parotid or other salivary glands without other apparent cause.
[86]
Laboratory Testing for Mumps - CDC
Jun 11, 2024 · CDC laboratories detected mumps RNA during both early and late episodes of parotitis. Both buccal swab and serum specimens should be collected ...Serology to Diagnose Mumps · Mumps Specimen Collection · Genetic AnalysisMissing: routes | Show results with:routes
[87]
Diagnostic Yield of Laboratory Methods and Value of Viral ...
The results from this study, along with those from previous studies, highlight the value of RT-PCR and genotyping during mumps outbreaks and inform clinical and ...
[88]
Mumps Specimen Collection - CDC
Jun 6, 2024 · Patients with suspected mumps should be tested by rRT-PCR to confirm mumps at the beginning of a suspected mumps outbreak.When Specimens Should Be... · Optimal Time To Collect... · Specimens To Collect
[89]
Real-Time Reverse Transcription-PCR Assay for Detection of ...
Real-time RT-PCR results showed 100% correlation with results from viral culture, the gold standard for mumps diagnostic testing. Assay efficiency was over 90% ...<|separator|>
[90]
Serology to Diagnose Mumps - CDC
Jun 5, 2024 · Serologic tests cannot differentiate between an exposure to vaccine and an exposure to wild-type mumps virus.
[91]
Comparison of the Sensitivity of Laboratory Diagnostic Methods from ...
Overall, the rRT-PCR-N assay detected mumps RNA in 94% (193/205) of the samples compared to 79% (161/205) using rRT-PCR-SH. No significant difference in the ...
[92]
Mumps Vaccine Recommendations - CDC
Sep 20, 2024 · Two doses of mumps vaccine are 86% (range: 32% to 95%) effective at preventing mumps. One dose is 72% (range: 49% to 91%) effective at preventing mumps.
[93]
Vaccines for measles, mumps, rubella, and varicella in children
Nov 22, 2021 · In unvaccinated children, 7.4% would catch mumps and this would fall to 1% if children were vaccinated with two doses. The results for rubella ( ...
[94]
Assessment of mumps-containing vaccine effectiveness by dose ...
Jun 8, 2022 · A French study concluded that the effectiveness of mumps vaccine waned with time and suggested boosting for individuals whose last dose was more ...
[95]
Modeling the population-level impact of a third dose of MMR vaccine ...
Oct 14, 2024 · Our models showed that early introduction of a third dose of MMR vaccine during a mumps outbreak can be effective in preventing transmission.
[96]
Strategies for the Control and Investigation of Mumps Outbreaks - CDC
Sep 20, 2024 · A mumps outbreak is defined as 3 or more cases linked by time and place. However, public health officials may implement mumps outbreak control ...<|separator|>
[97]
Updated Recommendations for Isolation of Persons with Mumps
Oct 10, 2008 · As a result, CDC, AAP, and HICPAC all now recommend a 5-day period after onset of parotitis, both for isolation of persons with mumps in either ...
[98]
Mumps | Infection Control - CDC
Apr 5, 2024 · Transmission of mumps virus occurs through deposition of respiratory, oral, or nasal secretions from an infected source person on the mucus ...
[99]
[PDF] Mumps Reporting and Investigation Guideline
However, mumps infection may present only with nonspecific or symptoms or may be a subclinical infection. Rates of classic parotitis among all age groups ...
[100]
Mumps - Ohio Department of Health
Jul 24, 2025 · Quarantine of close contacts is not routinely recommended. Known close contacts who are not part of a close contact setting or congregate ...
[101]
Lessons from managing a campus mumps outbreak using test, trace ...
Students who were exposed to mumps who did not have a verified history of MMR immunization were asked to quarantine by staying at their residence, not attending ...
[102]
Containing the spread of mumps on college campuses - PMC
Jan 26, 2022 · We applied a stochastic compartmental model to quantify the impact of university-level responses to contain a mumps outbreak at Harvard University in 2016.
[103]
Cleaning for Mumps Outbreaks and Prevention
May 31, 2019 · Cleaning in the event of, or to prevent mumps outbreaks requires adhering to a high standard of cleanliness and hygienic practices.
[104]
[PDF] GENERAL GUIDELINES FOR THE PREVENTION AND ... - NJ.gov
School Closure: Schools should work with LHDs to ensure that recommended control measures (e.g., exclusions, increased cleaning) are being followed. In ...
[105]
National Notifiable Diseases Surveillance System (NNDSS) - CDC
Apr 17, 2024 · NCIRD coordinates for 23 diseases and conditions, including vaccine-preventable diseases (VPDs) and other respiratory diseases and conditions.
[106]
NNDSS - TABLE 1Y. Mumps to Novel influenza A virus infections
Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data ...
[107]
Loss of protective immunity of two-dose mumps-containing vaccine ...
Feb 5, 2021 · The herd immunity threshold for block mumps transmission has been estimated at 86–93%, while the critical vaccination coverage was estimated as ...
[108]
Waning immunity most consistent with recent mumps outbreaks
Jan 10, 2023 · "We found that, due to the combination of waning immunity and primary vaccine failure, robust herd immunity cannot be achieved with the present ...
[109]
Guidelines for the Prevention and Control of Mumps Outbreaks ... - NIH
Mumps has a fairly long infectious period (up to 16 days) and a long incubation period (14 to 25 days), and 20% to 30% of infectious cases show no signs or ...
[110]
Universities' experience with mumps outbreak response and use of ...
During January 2016–June 2017, 75 mumps outbreaks occurred in US universities, despite high vaccine coverage among students. We evaluated universities' ...
[111]
The Resurgence of Mumps - U.S. Pharmacist
May 17, 2019 · The recent outbreaks and resurgence of mumps are thought to have occurred for multiple reasons, including declining levels of vaccine-derived immunity.
[112]
A Third Dose of Measles-Mumps-Rubella Vaccine to Improve ...
Waning of vaccine-induced immunity is considered to play a central role in the reemergence of mumps among vaccinated young adults. The aim of the present study ...Abstract · MATERIAL AND METHODS · RESULTS · Discussion
[113]
Impact of vaccine effectiveness and coverage on preventing large ...
Recent mumps outbreaks among highly vaccinated populations, including college students, have called into question the vaccine effectiveness (VE) of routine ...
[114]
Mumps - Diagnosis & treatment - Mayo Clinic
A care provider may diagnose mumps based on typical symptoms and known exposure to mumps. Tests used to look for the virus and diagnose mumps include:.Treatment · Preparing For Your... · What To Expect From Your...<|separator|>
[115]
Mumps Treatment & Management - Medscape Reference
Feb 6, 2025 · Patients diagnosed with mumps should be isolated for 5 days from the onset of symptoms to minimize the risk of infecting others. Also see ...Approach Considerations · Consultations and Transfer · Diet and Activity
[116]
Effects of Ribavirin on BHK-21 Cells Acutely or Persistently Infected ...
Ribavirin had marked antiviral activity against both the acute and persistent infections as determined by an inhibition of hemadsorption plaque formation.
[117]
Characteristics of a large mumps outbreak: Clinical severity ...
Patients with systemic symptoms and/or complications (419, 13.4%) were either hospitalized (n = 79) or treated in an emergency medical center (n = 340). The ...
[118]
Mumps Symptoms and Complications - CDC
Jun 5, 2024 · Mumps is a contagious disease caused by a virus that infects the salivary glands. Symptoms that might begin a few days before jaw swelling ...Missing: definition | Show results with:definition
[119]
Mumps Virus: Modification of the Identify-Isolate-Inform Tool for ...
Jun 30, 2016 · Other complications of mumps infection include meningitis, which may occur in up to 10% of cases. When meningitis does occur, it is typically ...Missing: prognosis statistics
[120]
Is mumps making a comeback? - PMC
Serious complications of mumps ... After approximately one week, the fever and swelling subside, and if there are no complications, recovery is complete (1,2).Missing: prognosis statistics
[121]
Mumps: A Call for Vigilance - The Journal for Nurse Practitioners
children had acquired mumps by age 15 months, resulting in lifelong immunity,2,10 This lifelong immunity was demonstrated in 95% of adults who had the mumps ...
[122]
History of mumps: Outbreaks and vaccine timeline - Mayo Clinic
1967. The first mumps vaccine is licensed by the U.S. Food and Drug Administration (FDA). Mumps had been a common cause of deafness.
[123]
Vaccination Status and Incidences of Measles, Mumps, and Rubella
Apr 25, 2025 · Rubella vaccine was implemented in 90.2% of countries, while mumps vaccine adoption remained lower at 63.9%. The African Region experienced high ...
[124]
[PDF] Mumps - AER 2023 - ECDC
Jul 22, 2025 · For 2023, 2 963 cases of mumps were reported to ECDC by 27 EU/EEA Member States with an overall notification rate of 0.7 cases per 100 000 ...
[125]
Majority of mumps cases are among the vaccinated, CDC finds
Dec 4, 2021 · As many as 94 percent of children and adolescents who contracted the highly contagious virus had been vaccinated.
[126]
Characteristics of Large Mumps Outbreaks in the United States, July ...
Twenty-three outbreaks with 20–485 cases per outbreak were reported in 18 jurisdictions. The duration of outbreaks ranged from 1.5 to 8.5 months (median, 3 ...Missing: epidemics | Show results with:epidemics
[127]
Mumps - Annual Epidemiological Report for 2023 - ECDC
Aug 4, 2025 · For 2023, 2 963 cases of mumps were reported to ECDC by 27 EU/EEA Member States with an overall notification rate of 0.7 cases per 100 000 ...
[128]
Characteristics of reported mumps cases in the United States: 2018 ...
Nov 14, 2024 · The incidence of mumps was highest among those aged 18-24 years during 2018-2020 (maximum of 4.54 cases per 100,000 persons in 2019), and ...Missing: gender | Show results with:gender
[129]
Understanding Mumps Dynamics - PubMed Central
Aug 29, 2024 · A total of 81.75% of the cases were students and childcare children, and the gender ratio was 1.5:1 (male/female). ... Notably, 89.14% (3692/4142) ...
[130]
Knowledge Gaps Persist and Hinder Progress in Eliminating Mumps
May 18, 2018 · Mumps spreads through respiratory droplets and contact. Initial vaccines contained inactivated virus and while effective, did not induce long- ...
[131]
Are Available Mumps Vaccines Effective Enough to Prevent ...
Vaccine effectiveness after 2 doses of mumps vaccine was reported in 3 outbreaks and ranged from 91% to 94.6%. There was evidence of waning immunity, which is a ...